COME CONTRIBUIRE

PUBBLICAZIONI SCIENTIFICHE

I risultati delle ricerche finanziate dalla Associazione in questi anni sono stati presentati

in numerosi convegni e congressi nazionali ed internazionali e pubblicati su importanti riviste scientifiche.
IMPACT FACTOR

L'impact factor dei lavori scientifici è attualmente di 2143,60 punti considerando l'I.F. più recente della rivista


  • Pubblicazione:
  • Journal Clinical Oncology Global Oncology (ISSN 2687-8941), 11-e2500139, 2025

158 – Impact of Ethnicity on Breast Cancer Outcome: A Systematic Review and Meta-Analysis of Randomized Phase III Trials of the Last Decade

  • AUTORI: Zattarin E., Moscetti L., D'Agostino E., Bertolotti A., Sperduti I., Chiavelli C., Canino F., Piacentini F., Cortesi L., Dominici M., Toss A.
Abstract Purpose: It remains uncertain whether ethnicity affects the benefit derived from novel breast cancer (BC) treatments. Thus, we conducted a systematic review and meta-analysis
  • Pubblicazione:
  • ESMO Open (ISSN 2059-7029), 12-105911, 2025

157 – Bridging language barriers in global oncology: toward more inclusive scientific communication

  • AUTORI: A Toss A.,, E Zattarin E., Moscetti L.., M Dominici M.
NO ABSTRACT AVAILABLE
  • Pubblicazione:
  • Communications Medicine - London (ISSN 2730-664X), 5:1-70, 2025

156 – Reduced reproductive potential in young healthy women with hereditary breast and/or ovarian cancer syndrome

  • AUTORI: Sighinolfi G., Grandi G., Barbieri E., Venturelli M., Piombino C., Melotti C., Lippi Bruni R., Costantini Cuoghi R., D'Amico R., Lambertini M., Peccatori F.A., Tenedini E., Dominici M., Cortesi L., La Marca A., Toss A.
Abstract Background: Young, healthy women carrying a pathogenic or likely pathogenic variant (P/LPV) in genes configuring the hereditary breast and/or ovarian cancer (HBOC) syndrome face
  • Pubblicazione:
  • Cancer Treatment Reviews (ISSN 0305-7372), 126-102723, 2024

155 – Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer

  • AUTORI: D'Agostino E., Mastrodomenico L., Ponzoni O., Baldessari C., Piombino C., Pipitone S., Giuseppa Vitale M., Sabbatini R., Dominici M., Toss A.
Abstract Endometrial cancer (EC) incidence and mortality rates have been increasing, particularly among young females. Although more than 90% of ECs are sporadic, 5-10%
  • Pubblicazione:
  • Cancer Medicne (ISSN 2045-7634), 14:22-e71377, 2025

154 – A Decade of Specialized Acute Care: Clinical Impact of an Oncology-Hematology Emergency Room Compared to General Emergency Services

  • AUTORI: Malavasi N., Ferrara L., Di Marco L., Saviola A., Postiglione R., Cantile F., Acquaviva G., Galassi L., Bergonzini A., Fiorani C., Scarabelli L., Dominici M., Luppi M., Longo G.
Abstract Background: The management of severe complications arising from newly diagnosed or existing cancer, as well as acute therapy-related side effects, is traditionally provided by
  • Pubblicazione:
  • Journal Clinical of Oncology Global Oncology (ISSN 2687-8941), 11:e2400344, 2025

153 – Cause- Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study

  • AUTORI: Cabrera M.E., Civallero M., Stepanishyna Y., Derio L., Skrypets T., Lois V., Vega V., Calderon S., Rojas H., Pizarro A., Mendoza M.G., Romero M., Rojas C., Oliva J., Intriago M., Rojas B., Conte L., Marcheselli L., Federico M.
Abstract Purpose: Hodgkin lymphoma (HL) is classified as the first malignancy to be cured by a combination of chemotherapy and radiotherapy. However, the life expectancy
  • Pubblicazione:
  • Hemasphere (ISSN 2572-9241), 9:4-e70105, 2025

152 – High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial

  • AUTORI: Gotti M., Yana Stepanishyna Y., Tetiana Skrypets T., Marcheselli L., Cristinelli C., Botto B., Tonino S., Cavalieri D., Pulsoni A., Hutchings M., Hammoud M., Fortpied C., Rigacci L., Plattel W., Andrè M., Federico M.
No abstract available
  • Pubblicazione:
  • Cancer Reports (ISSN: 2573-8348), 7:12-e70028, 2O24

151 – Low Incidence of Cancer Recorded in the Galapagos Archipelago

  • AUTORI: Chisesi S.N., Rugge M., Galli G.R., Manni M., Luzuriaga Delgado V.M., Chisesi, T., Ruiz J.C., Mariuxi R., Briones Q., Siculella L., Guzzinati S., Zorzi M., Federico M., Iannone A.
Abstract Background: Cancer incidence in the Galapagos archipelago is unknown. Aim: In 2021, a task force including Ecuadorian and Italian researchers was established to estimate cancer
  • Pubblicazione:
  • British Journal of Haematology (ISSN 0007-1048), 205:1-166:174, 2024

150 – Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project

  • AUTORI: Monica Civallero, Joseph G Schroers-Martin, Steven Horwitz, Martina Manni, Yana Stepanishyna, Maria Elena Cabrera, Julie Vose, Michele Spina, et al.
Abstract Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, a subset of patients experience durable
  • Pubblicazione:
  • British Journal of Haematology (ISNN 0007-1048), 204:5-1757:1761, 2024

149 – Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021

  • AUTORI: Yana Stepanishyna, Martina Manni, Monica Civallero, Nazar Shokun, Tetiana Skrypets, Alevtyna Burtna, Natalia Shapovalenko, et al.
Abstract We report the outcome of 563 cases of newly diagnosed lymphoma registered in 2019-2021, including 176 cases (31.2%) of Hodgkin lymphoma (HL), 130
  • Pubblicazione:
  • Clinical Case Report (ISSN 2050-0904), 11:8-e7747, 2023

148 – Management of PALB2-associated breast cancer: a literature review and case report

  • AUTORI: Toss A., Ponzoni O., Riccò B., Piombino C., Moscetti L., Combi F., Palma E., Papi S., Tenedini E., Tazzioli G., Dominici M., Cortesi L.
Abstract Germline pathogenic variants (PV) of the PALB2 tumor suppressor gene are associated with an increased risk of breast, pancreatic, and ovarian cancer. In previous research, PALB2-associated
  • Pubblicazione:
  • Oncologist (ISSN 1083-7159), 28:10-e884:e890, 2023 - I.F. 5,8

147 – Healthcare professional communication on sexual health: a report from the Italian Working Group on adolescents and young adults with cancer

  • AUTORI: Quarello P., Toss A., Berchiella P., Mascarin M., Lambertini M., Canesi M., Milano G.M., Incorvaia L., Banna G.L., Peccatori F., Ferrari A.
Abstract Background: Sexual function is an important concern for adolescent and young adult (AYA) with cancer. The aim of this study was to explore the
  • Pubblicazione:
  • Genes (ISSN 2073-4425), 14-3:684, 2023 - I.F. 3,5

146 – Personalized systemic therapies in hereditary cancer syndromes

  • AUTORI: Mastrodomenico L., Piombino C., Riccò B., Barbieri e
Abstract Hereditary cancer syndromes are inherited disorders caused by germline pathogenic variants (PVs) that lead to an increased risk of developing certain types of
  • Pubblicazione:
  • ESMO Open (ISSN 2059-7029), 2023 - I.F. 7,3

145 – A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)

  • AUTORI: Cortesi L., Venturelli M., Cortesi G., Caggia F., Toss A., Barbieri E., De Giorgi U., Guarneri V., Musolino A., De Matteis E., Zambelli A., Bisagni G., Dominici M.
Abstract Background BRCA1/2-related metastatic breast cancers (mBC) are sensitive to DNA-damage agents and show high tumor-infiltrated lymphocytes. We hypothesized that the association between pembrolizumab
  • Pubblicazione:
  • Hematology Oncology (ISSN 1099-1069), 41:4-655:662, 2023

144 – Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naive advanced-stage follicular lymphoma: a subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi

  • AUTORI: Nizzoli M.E., Manni M., Ghiggi C., Pulsoni A., Musuraca G., Merli M., Califano C., Bari A., Massaia M., Conconi A., Musto P., Mannina D., Perrone T., Re F., Galimberti S., Gini G., Capponi M., Vitolo U., Usai S.V., Stefani P.M., Ballerini F., Liberati A.M
Abstract We conducted a post hoc analysis of the FOLL12 trial to determine the impact of different initial immunochemotherapy (ICT) regimens on patient outcomes.
  • Pubblicazione:
  • HemaSphere (ISSN 2572-9241), 7-4:e866, 2023 - I.F. 8,3

143 – La Cantera: “A star is born” in hematology

  • AUTORI: Dreyling M., Manni M., Federico M.
ABS NOT AVAILABLE
  • Pubblicazione:
  • Frontiers in Oncology 12-10162958, 2022 - I.F. 4,7

142 – Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy

  • AUTORI: Toss A., Venturelli M., Civallero M., Piombino C., Domati F., Ficarra G., Combi F., Cabitza E., Caggia F., Barbieri E., Bartolini M., Moscetti L., Omarini C., Piacentini F., Tazzioli G., Dominici M., Cortesi L.
Abstract Introduction: Triple-negative breast cancer (TNBC) patients who do not obtain pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) present higher rate of relapse and
  • Pubblicazione:
  • Hematological Oncology 40-5:953-961, 2022 - I.F. 4,85

141 – Characteristics and clinical outcomes of patients with ALK- Positive anaplastic large cell lymphoma: report from the Prospective International T-Cell Lymphoma Project

  • AUTORI: Chiattone C., Civallero M., Fischer T., Miranda M., Zing N.P.C., Pileri S.A., Montoto S., Horwitz S.M., Cabrera M.E., De Souza C.A., Nagler A., Luminari S., Ferreri A.J.M., Carson K.R., Re A., Rigacci L., Nassi L., Stepanishyna Y., Federico M., Inghiran
Abstract The T-cell Lymphoma Project is an international registry prospective study that enrolled patients with newly diagnosed peripheral T-cell and NK-cell lymphomas (PTCL). The
  • Pubblicazione:
  • Hematological Oncology, 2022 - I.F. 5,27

140 – Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification

  • AUTORI: Kriachok I., Stepanishyna Y., Skrypets T., Shokun N., Martvnchyk A., Tytoremko I., Aleksik O., Krotevych M., Manni M., Federico M.:
Abstract The Ukrainian Lymphoma Registry (ULR) was established in 2019 with the aim of monitoring the quality of diagnosis, staging, and treatment of lymphoma
  • Pubblicazione:
  • Cancer, 2021 - I.F. 5,73

139 – Insights into the possible molecular mechanisms of resistance to PARP inhibitors

  • AUTORI: Piombino C., Cortesi L.
Abstract PARP1 enzyme plays an important role in DNA damage recognition and signalling. PARP inhibitors are approved in breast, ovarian, pancreatic, and prostate cancers
  • Pubblicazione:
  • Journal of Clinical Oncology 40-7:729-739, 2021 - I.F. 44,54

136 – Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study

  • AUTORI: Luminari S., Manni M., Galimberti S., Versari A., Tucci A., Boccomini C., Farina L., Olivieri J., Marcheselli L., Guerra L., Ferrero S., Arcaini L., Cavallo F., Kovalchuk S., Skrypets T., Del Giudice I., Chauvie S., Patti C., Stelitano C., Ricci F., Pinto
Abstract Purpose: We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction
  • Pubblicazione:
  • Biomedicines 9:3-312, 2021 - I.F. 4,71

132 – The Role of Exosomes in Breast Cancer Diagnosis

  • AUTORI: Piombino C., Mastrolia I., Omarini C., Candini O., Dominici M., Piacentini F., Toss A.
Abstract: The importance of molecular re-characterization of metastatic disease with the purpose of monitoring tumor evolution has been acknowledged in numerous clinical guidelines for
  • Pubblicazione:
  • British Journal of Haematology 192:6-1011:1014, 2021 - I.F. 5,02

126 – Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma

  • AUTORI: Massaro F., Stepanishyna Y., Manni M., Luminari S., Galimberti S., Marcheselli L., Visco C. et al.
Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the MCL01 trial, patients were treated with the R-HCVAD regimen [rituximab plus HyperCVAD
  • Pubblicazione:
  • Journal of Clinical Oncology 36:7-689:696, 2018 - I.F. 28,24

121 – Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma

  • AUTORI: Luminari S., Ferrari A., Manni M., Dondi A., Chiarenza A., Merli F. et al.
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab
  • Pubblicazione:
  • Cancers 11:2-193:204, 2019 - I.F. 6,12

119 – Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies

  • AUTORI: Toss A., Venturelli M., Molinaro E., Pipitone S., Barbieri E., Marchi I., Tenedini E., Artuso L., Castellano S., Marino M., Tagliafico E., Razzaboni E., De Matteis E., Cascinu S., Cortesi L.
The identification of BRCA mutations plays a crucial role in the management of hereditary cancer prevention and treatment. Nonetheless, BRCA-testing in pancreatic cancer (PC)
  • Pubblicazione:
  • Oncology 93:6-377:386, 2017 - I.F. 2,93

114 – Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo- Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study

  • AUTORI: Cortesi L., De Matteis E., Toss A., Marchi I., Medici V., Contu G. et al.
Objective: To evaluate the effectiveness of transvaginal ultrasound (TVU) and serum CA-125 measurement in women at different risk of developing ovarian cancer/fallopian tube cancer
  • Pubblicazione:
  • Hematological Oncology 35:4-630:636, 2016 - I.F. 5,27

111 – Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study

  • AUTORI: Bellei M., Sabattini E., Pesce EA., Ko YH., Kim WS., Cabreras ME. et al.
Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post-thymic lymphoid cells at different stages of differentiation with different
  • Pubblicazione:
  • BioMed Research International 1:12, 2015 - I.F. 3,41

108 – Activity of BKM120 and BEZ235 against lymphoma cells

  • AUTORI: Civallero M., Cosenza M., Pozzi S., Bari A., Ferri P., Sacchi S.
Non-Hodgkin lymphomas encompass a heterogeneous group of cancers, with 85–90% arising from B lymphocytes and the remainder deriving from T lymphocytes or NK lymphocytes.

RICERCA SUL CANCRO

PUBBLICAZIONI SCIENTIFICHE

Tutti i nostri articoli pubblicati sulle riviste scientifiche
VAI

PROGETTI DI RICERCA

I progetti di ricerca che abbiamo sostenuto
VAI

BORSE DI STUDIO E STAGE ALL'ESTERO

Borse di studio e stage all'estero per ricercatori finanziati dall'Associazione
VAI

PREMI DI STUDIO

Stage all'estero per ricercatori sostenuti dall'Associazione
VAI

PREMIO "PIER CAMILLO BECCARIA"

Conferito ogni anno ad un illustre studioso che si è distinto nella lotta contro i tumori
VAI